title: Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
authors.forename: Renier
authors.initials: R
authors.lastname: Brentjens
authors.forename: Raymond
authors.initials: R
authors.lastname: Yeh
authors.forename: Yvette
authors.initials: Y
authors.lastname: Bernal
authors.forename: Isabelle
authors.initials: I
authors.lastname: Riviere
authors.forename: Michel
authors.initials: M
authors.lastname: Sadelain
mesh_terms: D000368:Aged; D018941:Antigens, CD19 / Q000235:genetics / Q000276:immunology; D018106:CD28 Antigens / Q000235:genetics / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D017809:Fatal Outcome; D018390:Gene Targeting; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000628:therapy*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*
chemical_list: D018941:Antigens, CD19; D018106:CD28 Antigens; D011993:Recombinant Fusion Proteins; D003520:Cyclophosphamide